Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors

被引：0

作者：

Berardi, R. ^{[1
]}

Torniai, M. ^{[1
]}

Pusceddu, S. ^{[2
]}

Spada, F. ^{[3
]}

Brizzi, M. P. ^{[4
]}

Ibrahim, T. ^{[5
]}

Antonuzzo, L. ^{[6
]}

Ferolla, P. ^{[7
]}

Panzuto, F. ^{[8
]}

Silvestris, N. ^{[9
]}

Partelli, S. ^{[10
]}

Bongiovanni, A. ^{[5
]}

Zichi, C. ^{[4
]}

Riva, N. ^{[5
]}

Rinzivillo, M. ^{[8
]}

机构：

[1] Univ Politecn Marche, Ancona, Italy

[2] INT, Milan, Italy

[3] IEO, Milan, Italy

[4] San Luigi Hosp, Orbassano, Italy

[5] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy

[6] AOU Careggi, Florence, Italy

[7] Osped S Maria Misericordia, Perugia, Italy

[8] Sapienza Univ Rome, St Andrea Hosp, Sch Med, Rome, Italy

[9] Cancer Inst Giovanni Paolo II, Bari, Italy

[10] Univ Vita & Salute, Osped San Raffaele IRCCS, Milan, Italy

来源：

NEUROENDOCRINOLOGY | 2016年 / 103卷

关键词：

PNET; Dose intensity; Targeted therapy; Everolimus; Cumulative dose;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：77 / 77

页数：1

共 50 条

[21] When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors? Reply
Yao, James C.
Voi, Maurizio
Lincy, Jeremie
Pavel, Marianne
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) : 1488 - +
[22] Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus
Cella, C. A.
Barberis, M.
Spada, F.
Pisa, E.
Laffi, A.
Gritti, S.
Leone, I
Zanetti, C.
Fazio, N.
NEUROENDOCRINOLOGY, 2018, 106 : 4 - 4
[23] Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Viudez, Antonio
Crespo, Guillermo
Dorronsoro, Maria Luisa Gomez
Arozarena, Imanol
Marin-Mendez, Juan Jesus
Custodio, Ana
Benavent, Marta
Goni, Saioa
Garcia-Paredes, Beatriz
Hern, Jorge
Durantez, Maika
Alonso, Vicente
Riesco, Del Carmen
Lopez, Carlos
Jimenez-Fonseca, Paula
San Vicente, Borja Lopez
Gonzalez-Borja, Iranzu
Sevilla, Isabel
Hernandez-Garcia, Irene
Carmona-Bayonas, Alberto
Capdevila, Jaume
Perez-Sanz, Jairo
Garcia-Carbonero, Rocio
Perez-Ricarte, Leyre
Llanos, Marta
Vera, Ruth
De Jesus Acosta, Ana
PANCREATOLOGY, 2021, 21 (01) : 215 - 223
[24] Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations
Liu, Eric
Marincola, Paula
Oberg, Kjell
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2013, 6 (05) : 412 - 419
[25] Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus
Cella, C. A.
Spada, F.
Labanca, V
Radice, D.
Rubino, M.
Zorzino, L.
Fazio, N.
NEUROENDOCRINOLOGY, 2017, 105 : 3 - 3
[26] Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors - Experiences from a tertiary referral center
Kiesewetter, Barbara
Melhorn, Philipp
Macheiner, Simon
Wolff, Ladislaia
Kretschmer-Chott, Elisabeth
Haug, Alexander
Mazal, Peter
Raderer, Markus
JOURNAL OF NEUROENDOCRINOLOGY, 2023,
[27] Application of low dose pancreas perfusion CT combined with enhancement scanning in diagnosis of pancreatic neuroendocrine tumors
Wan, Yamin
Hao, Hui
Meng, Saisai
Li, Zhizhen
Yu, Fulong
Chi, Meng
Chao, Qi
Gao, Jianbo
PANCREATOLOGY, 2021, 21 (01) : 240 - 245
[28] Symptomatic Control of Neuroendocrine Tumors with Everolimus
Bainbridge, H.
Larbi, E.
Middleton, G.
NEUROENDOCRINOLOGY, 2012, 96 : 18 - 18
[29] Multiple intracardiac benign tumors treated with low-dose everolimus
Beyazal, Meryem
Ozyazici, Ahmet
Yesil, Sule
ANATOLIAN JOURNAL OF CARDIOLOGY, 2022, 26 (02): : 141 - 142
[30] The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors
Nunez, Jose Eduardo
Donadio, Mauro
Rocha Filho, Duilio
Rego, Juliana Florinda
Barros, Milton
Formiga, Maria Nirvana
Lopez, Rossana
Riechelmann, Rachel
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (04) : 645 - 651

← 1 2 3 4 5 →